The effect of butylscopolamine on [¹⁸F]FDG uptake in the gastrointestinal tract is negligible and regionally variable.

ABSTRACT:

Background

Butylscopolamine (or hyoscine butylbromide, trade name Buscopan^®) is occasionally administered as a premedication to reduce non-specific FDG uptake in the gastrointestinal tract based on its antiperistaltic effect. To date, there are no consistent recommendations for its use. The aim of this study was to quantify the reduction in intestinal and non-intestinal uptake by butylscopolamine administration and to derive relevance for clinical evaluation.

Results

458 patients (PET/CT for lung cancer) were retrospectively reviewed. 218 patients with butylscopolamine and 240 patients without butylscopolamine had comparable characteristics. While the SUV_mean in the gullet/stomach and small intestine was significantly reduced with butylscopolamine, the

SUBMITTER: Guhne F 

PROVIDER: S-EPMC10281937 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature